Viral Rebound Uncommon After Molnupiravir, Nirmatrelvir-Ritonavir Therapy
FRIDAY, Dec. 9, 2022 (HealthDay News) — Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased mortality risk, according to a study published online Dec. 6 in JAMA …
Learn MoreRecommendations Updated for Treatment, Prevention of HIV
FRIDAY, Dec. 9, 2022 (HealthDay News) — In a special communication article published online Dec. 1 in the Journal of the American Medical Association, the International Antiviral Society-USA Panel presents updated recommendations for the use of antir…
Learn MoreJYNNEOS Vaccination Provides Protection Against Mpox
THURSDAY, Dec. 8, 2022 (HealthDay News) — Among men aged 18 to 49 years who are eligible for the JYNNEOS vaccine, mpox incidence is considerably higher among unvaccinated persons versus those who received one or two vaccine doses, according to resea…
Learn More~10 Percent of Deaths Among Ever-Employed Linked to COPD in 2020
THURSDAY, Dec. 8, 2022 (HealthDay News) — About 10 percent of deaths among ever-employed persons aged 15 years and older were associated with chronic obstructive pulmonary disease (COPD) in 2020, according to research published in the Dec. 9 issue o…
Learn MoreMost Common Adverse Events With JYNNEOS Are Nonserious
THURSDAY, Dec. 8, 2022 (HealthDay News) — The JYNNEOS vaccine, which is recommended for persons exposed to or at high risk for exposure to mpox virus, seems safe, with the most common adverse health events reported as nonserious, according to resear…
Learn MoreMRI-Targeted Biopsy Beneficial for Men With Elevated PSA
THURSDAY, Dec. 8, 2022 (HealthDay News) — For men with elevated prostate-specific antigen (PSA) levels, magnetic resonance imaging (MRI)-directed targeted biopsy seems better for screening and early detection than systematic biopsy, according to a st…
Learn MoreTumor-Infiltrating Lymphocytes Up PFS in Advanced Melanoma
THURSDAY, Dec. 8, 2022 (HealthDay News) — For patients with advanced melanoma, infusion of tumor-infiltrating lymphocytes (TIL) is associated with significantly longer progression-free survival than ipilimumab treatment, according to a study publishe…
Learn MoreSupplementation of Some Micronutrients May Improve CVD Outcomes
THURSDAY, Dec. 8, 2022 (HealthDay News) — Supplementation of some micronutrients may reduce cardiovascular disease (CVD) outcomes, according to a review published in the Dec. 13 issue of the Journal of the American College of Cardiology.Peng An, Ph.D…
Learn MoreIntervention Delivered Via Web-Based Platform Ups BP Control
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — A multicomponent intervention delivered on a web-based platform can improve blood pressure (BP) control among individuals with hypertension, according to a study published online Dec. 7 in JAMA Network Open….
Learn MoreStatin Use Linked to Reduced Risk for Intracerebral Hemorrhage
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — Statin use, especially prolonged statin use, is associated with a reduced risk for intracerebral hemorrhage (ICH), according to a study published online Dec. 7 in Neurology.Nils Jensen Boe, M.D., from Odense…
Learn More